<< Exhibitor
<< Press release
The 24th China International In Vitro Diagnostics by CACLP will officially take place 19-21 March 2027 at the Nanjing International Expo Center in Nanjing, Jiangsu Province, China.
The 23rd China International In Vitro Diagnostics by CACLP was successfully held from 21-23 March 2026 in Xiamen, marking another milestone in the event’s continued expansion across China, Southeast Asia and the global market.
In order to promote innovative exchanges and cross-regional cooperation in the global in vitro diagnostics field, the 1st Global IVD Innovation Summit is scheduled to be held in Xiamen on March 22, 2026, during CACLP 2026. Hereby notify the relevant matters as follows:
As artificial intelligence and digital twin technologies rapidly reshape the global healthcare landscape, their integration into clinical practice, laboratory medicine, and biomedical research is opening new frontiers for precision, efficiency, and system-level optimization.
Amid the deepening implementation of the Healthy China 2030 strategy and the rapid convergence of a new global biotechnology revolution, in vitro diagnostics (IVD) has become more critical than ever.
The 11th China Experimental Medicine Conference, themed “Innovation Shaping the Future,” will be held from 21-22 March, 2026, in Xiamen.
As a vital link between innovation and clinical application, IVD distribution enterprises play an indispensable role in ensuring the efficient flow of diagnostic products and services.
Driven by rapid advances in healthcare technology, the IVD industry is entering a new era of innovation and growth. Enlightening Lab Med —— The 9th IVD Youth Entrepreneur Forum will take place on 21 March 2026 at the Xiamen International Expo Center.
As the global in vitro diagnostics (IVD) industry advances toward greater technological sophistication, intelligent automation, and broader clinical applications, the focus of innovation is shifting upstream. Beyond the development of cutting-edge instruments and assays, increasing attention is being placed on the foundational elements that enable performance and reliability—namely critical raw materials, core components, and robust standards systems. Breakthroughs in advanced materials, precision-engineered components, and cross-disciplinary integration are becoming central drivers of sustainable industry growth.
With less than one month remaining before its official opening, the 23rd China International In Vitro Diagnostics by CACLP, together with a series of academic conferences, industry forums, and business meetings, has entered its final countdown stage.
<< Industry news
Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.
Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the VENTANAⓇ PTEN (SP218) RxDx Assay is the first immunohistochemistry (IHC) companion diagnostic test to receive U.S. Food and Drug Administration (FDA) approval for determining PTEN protein loss, also known as PTEN deficiency, in tumours of patients with prostate adenocarcinoma. These patients may now be eligible for treatment with AstraZeneca’s targeted therapy TRUQAPⓇ (capivasertib).
Cepheid, a Danaher company, today announced it has donated an initial shipment of Xpert® Hemorrhagic Fever panel tests to support the diagnostic response to the Ebola Bundibugyo (BDBV) outbreak in the Democratic Republic of the Congo (DRC) and Uganda. The World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern on May 17, 2026.
Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the European Union In Vitro Diagnostic Regulation (IVDR) approval of several label expansions for the VENTANA® MMR RxDx Panel, an immunohistochemistry (IHC) companion diagnostic test that aids in identifying a cancer patient’s mismatch repair (MMR) status. MMR is a process that scans a person’s genetic code and fixes errors to prevent mutations that can lead to cancer. The test evaluates a panel of MMR proteins in tumours to provide this important treatment information to clinicians.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) for Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option.
Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings.
Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD marking in compliance with the European Union’s In Vitro Diagnostic Regulation (IVDR).
It is foreseeable that development trend of Blood typing reagent technologies is mainly reflected by improvement of Blood typing accuracy, increase in Blood typing efficiency and reduction of test time; improvement of Blood typing sensitivity and prevention of missed test; evaluation of antibody titer determination and other aspects.
Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses Photocure's blue light cystoscopy (BLC®) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.
<< Video showcase
Talk with Prof. Leslie Lam at CACLP 2026
Talk with Prof. Vittorio Sambri at CACLP 2026
Talk with Prof. Sergio Bernardini at CACLP 2026
Talk with Prof. Rajiv Erasmus at CACLP 2026
Talk with Prof. Aldo Tomasi at CACLP 2026
Talk with Yinan Tang at CACLP 2026
Talk with Shaoting Zhang at CACLP 2026
Talk with Huai Chen at CACLP 2026
Talk with CHIA Wai Kian at CACLP 2026
Talk with Rahul AGARWAL at CACLP 2026
Talk with Jag Grewal at CACLP 2026
CACLP 2026 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
The 13th China IVD Industry Development Conference & The 11th China Experimental Medicine Conference
CACLP International Night 2026
The 1st Global IVD Innovation Summit
Go Global: China IVD International Forum 2026
CACLP 2025 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
The 12th China IVD Industry Development Conference (CIIDC)
The 10th China Experimental Medicine Conference (CEMC)
International Laboratory Medicine and In Vitro Diagnostic Forum
<< Download centre
CACLP 2026 Floor Plan
CACLP 2026 Full Schedule
CACLP 2026 Exhibitor Manual
CACLP 2025 Post-show Report
CACLP 2025 Post-show Press Release
CACLP 2025 Exhibitor Manual
CACLP 2025 Floor Plan
CACLP 2025 Full Schedule
CACLP & CISCE 2024 Draw Global Attention to Innovations and Collaborations in IVD Industry
CACLP & CISCE to present the latest in IVD with 1300+ Exhibitors and 100+ Concurrent Activities this March in Chongqing.pdf
Copyright © 2026 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.